Reaction
Rectal Tenesmus reporting signals
As of the last recalculation, Rectal Tenesmus appears in 1,215 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 46.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vedolizumab | 197 | 46.6 | 46.7 |
| Mesalamine | 120 | 40.5 | 40.6 |
| Infliximab-Dyyb | 54 | 33.1 | 33.1 |
| Leucovorin Calcium | 22 | 20.1 | 20.1 |
| Calcitriol Capsules 0.25 Mcg | 20 | 17.4 | 17.4 |
| Calcitriol Capsules 0.5 Mcg | 20 | 17.4 | 17.4 |
| Calcitriol | 20 | 17.2 | 17.2 |
| Linaclotide | 23 | 15.0 | 15.0 |
| Lubiprostone | 7 | 12.7 | 12.8 |
| Fluorouracil Cream, 0.5% | 52 | 12.2 | 12.2 |
| Panitumumab | 11 | 12.1 | 12.1 |
| Fluorouracil | 52 | 12.0 | 12.0 |
| Tamsulosin Hydrochloride | 14 | 11.9 | 11.9 |
| Loperamide Hydrochloride Oral | 7 | 11.8 | 11.8 |
| Oxaliplatin | 45 | 10.8 | 10.8 |
| Irinotecan Hydrochloride | 8 | 10.7 | 10.7 |
| Capecitabine | 47 | 9.1 | 9.1 |
| Rifaximin | 9 | 7.4 | 7.4 |
| Orlistat | 9 | 6.0 | 6.0 |
| Cetuximab | 10 | 5.5 | 5.5 |
| Aflibercept | 9 | 5.0 | 5.0 |